Cannabis compound CBG shows promise for depression and memory in early studies

Depression affects millions worldwide, but conventional antidepressants fail for nearly 40% of patients, creating an urgent need for new treatment options. This preclinical study examined five different phytocannabinoids—compounds found naturally in cannabis—to see which ones might help with depression and cognitive problems. Researchers tested cannabichromene, cannabidiol (CBD), cannabidivarin, cannabigerol (CBG), and cannabinol in laboratory cells and mouse models of depression. The results were surprising: cannabigerol emerged as the standout candidate, showing strong antidepressant-like effects in healthy mice and significantly improving cognitive performance in depressed mice, particularly through increased dendritic spine density in the hippocampus—a brain region crucial for learning and memory.

The study revealed important differences between cannabinoids. While CBD showed strong anti-inflammatory effects, it failed to improve depression or cognitive deficits in the stressed mice. Cannabidivarin, despite demonstrating anti-inflammatory activity, actually worsened anxiety and damaged cognitive function, highlighting that not all cannabinoids are universally beneficial. By contrast, cannabigerol proved safe with low cytotoxicity and delivered measurable benefits: a single dose improved mood-like behavior in healthy animals, while multiple doses enhanced cognitive function in depressed animals. The researchers also found that CBD and cannabidivarin were the strongest anti-inflammatory agents, reducing key inflammatory markers like iNOS and pro-IL1β levels.

These unprecedented findings suggest that cannabigerol may offer therapeutic potential for mood and cognitive disorders, potentially addressing the treatment gap left by conventional antidepressants. The research demonstrates why studying individual cannabinoids is critical—each has distinct effects and safety profiles. While these are preclinical results requiring human clinical trials before medical application, the work opens promising avenues for developing novel antidepressant treatments with pleiotropic effects (multiple beneficial actions) that current drugs cannot match.